AVLX-144 is under clinical development by Avilex Pharma and currently in Phase I for Acute Ischemic Stroke. According to GlobalData, Phase I drugs for Acute Ischemic Stroke have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AVLX-144’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVLX-144 (UCCB-01144) is under development for the treatment of acute ischemic stroke, chronic inflammatory pain, neuropathic pain and subarachnoid hemorrhage. It is a dimeric peptide in which cell penetrating peptide (CPP) is linked by an amide bond to a symmetric NPEG linker. The drug candidate acts by targeting PSD-95.
Avilex Pharma overview
Avilex Pharma is a biotech company with technology developed at the department of drug design and pharmacology of the university of copenhagen. The company also develops dimeric peptides that target for the treatment of neuropathic pain. It is headquartered in Copenhagen, Frederiksberg, Denmark.
For a complete picture of AVLX-144’s drug-specific PTSR and LoA scores, buy the report here.